Gujarat Themis Sets ₹404 Price for ₹335 Crore Preferential Issue

Gujarat Themis Biosyn Limited plans to issue up to 82,92,081 shares at ₹404 each, raising about ₹335 crore.
Around ₹310 crore of the proceeds is earmarked for debt repayment linked to the MicroBiopharm Japan acquisition.

Reader Takeaway: The capital raise can reduce acquisition-linked debt, but the large equity issuance will dilute existing shareholders.

What just happened

Gujarat Themis Biosyn has issued a corrigendum to Resolution No. 8 of its 45th Annual General Meeting notice, revising the detailed terms of its proposed preferential allotment to comply with SEBI ICDR requirements.

The issue price has been fixed at ₹404 per equity share. The calculated floor price is ₹403.82, based on the 10-day volume-weighted average price preceding the relevant date of August 31, 2026.

The company proposes to issue up to 82,92,081 shares for total consideration of ₹335,00,00,724.

Why this matters

The proposed fundraising is closely tied to the company's acquisition financing rather than a general expansion programme.

Of the total proceeds, ₹310,00,00,724 is intended for redemption of non-convertible debentures and/or repayment or prepayment of borrowings raised for the acquisition of a 100% stake in MicroBiopharm Japan Co., Ltd.

Another ₹25 crore is allocated for general corporate purposes.

The transaction therefore has two opposing effects for shareholders: it can reduce acquisition-related leverage, but it also increases the equity base and creates dilution.

What changes now

The names of the proposed allottees remain unchanged, although the share allocations have been updated under the revised pricing structure.

Pharmaceutical Business Group (India) Limited is proposed to receive 61,88,121 shares for about ₹250 crore. Other proposed investors include Yusuf Khwaja Hamied, Special Situation India Fund, India Special Assets Fund III and ISAF III Onshore Fund.

The company has appointed India Ratings and Research Private Limited as the monitoring agency for utilisation of the issue proceeds.

Risks to watch

The key investor issue is dilution. Issuing up to 82.92 lakh new shares will expand the outstanding equity base if shareholders approve the proposal and the allotment is completed.

Execution of the debt reduction also matters. Investors should track whether the ₹310 crore allocation materially improves interest burden and balance-sheet flexibility after the MicroBiopharm Japan transaction.

What to track next

The next major trigger is the September 30, 2026 AGM, where shareholders are expected to consider the revised resolution.

Investors should then monitor final allotment, changes in shareholding, deployment of the ₹335 crore proceeds and the resulting impact on leverage and acquisition integration.